ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials
- PMID: 17135809
- DOI: 10.1097/01.wad.0000213873.25053.2b
ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials
Abstract
Background: In primary prevention trials for Alzheimer disease, the inception cohort typically has normal or minimally impaired complex activities of daily living (ADL). ADL change during a trial could trigger detailed evaluation or serve as an outcome measure. A brief, easily administered, and reliable ADL rating scale would assist prevention studies.
Objectives: To develop an ADL scale for prevention trials that allows self-rating or completion by informants.
Methods: The Activities of Daily Living-Prevention Instrument (ADL-PI) was developed, comprising 15 ADL and 5 physical function questions. Six hundred forty-four elderly subjects participating in the Prevention Instrument Project completed a self-rated version of the ADL-PI, and informants for 632 subjects completed an informant version. Informants also completed a Mild Cognitive Impairment (MCI) ADL questionnaire to allow comparisons.
Results: Subjects performed well on all ADL scales at baseline. Completion of the ADL-PI questionnaires at home or in-clinic yielded comparable information. Scores from baseline to 3 months had good reliability. The ADL-PI, obtained from either self-report or informants, discriminated between subjects rated as CDR 0 and CDR 0.5. Subjects with worse baseline cognitive performance also had slightly worse ADL-PI scores. Preliminary analysis indicates that subjects who triggered cognitive evaluations had slightly lower baseline ADL-PI scores by both self and informant reports.
Conclusions: The ADL-PI can be completed at home or in clinic, and has adequate reliability. The utility of self-administered and informant versions and predictive value of reported deficits requires further follow-up.
Similar articles
-
ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions.Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S124-38. doi: 10.1097/01.wad.0000213878.47924.44. Alzheimer Dis Assoc Disord. 2006. PMID: 17135806
-
ADCS Prevention Instrument Project: overview and initial results.Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S109-23. doi: 10.1097/01.wad.0000213870.40300.21. Alzheimer Dis Assoc Disord. 2006. PMID: 17135805 Clinical Trial.
-
ADCS Prevention Instrument Project: behavioral measures in primary prevention trials.Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S147-51. doi: 10.1097/01.wad.0000213872.17429.0f. Alzheimer Dis Assoc Disord. 2006. PMID: 17135808 Clinical Trial.
-
Assessment of functional ability in Alzheimer disease: a review and a preliminary report on the Cleveland Scale for Activities of Daily Living.Alzheimer Dis Assoc Disord. 1992 Fall;6(3):145-63. Alzheimer Dis Assoc Disord. 1992. PMID: 1485930 Review.
-
Critical appraisal of questionnaires to assess functional impairment in individuals with mild cognitive impairment.Int Psychogeriatr. 2016 Sep;28(9):1425-39. doi: 10.1017/S104161021600017X. Epub 2016 Apr 13. Int Psychogeriatr. 2016. PMID: 27072886 Review.
Cited by
-
Four-year outcome of mild cognitive impairment: the contribution of executive dysfunction.Neuropsychology. 2013 Jan;27(1):95-106. doi: 10.1037/a0030481. Epub 2012 Oct 29. Neuropsychology. 2013. PMID: 23106114 Free PMC article.
-
Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.J Alzheimers Dis. 2020;78(3):989-1010. doi: 10.3233/JAD-200896. J Alzheimers Dis. 2020. PMID: 33074237 Free PMC article. Clinical Trial.
-
Apathy, Executive Function, and Emotion Recognition Are the Main Drivers of Functional Impairment in Behavioral Variant of Frontotemporal Dementia.Front Neurol. 2022 Jan 13;12:734251. doi: 10.3389/fneur.2021.734251. eCollection 2021. Front Neurol. 2022. PMID: 35095710 Free PMC article.
-
Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial.Alzheimers Res Ther. 2023 Oct 23;15(1):183. doi: 10.1186/s13195-023-01325-3. Alzheimers Res Ther. 2023. PMID: 37872582 Free PMC article. Clinical Trial.
-
Chanwuyi Lifestyle Medicine Program Improves Memory and Executive Functions of Older Adults With Mild Cognitive Impairment.Am J Alzheimers Dis Other Demen. 2024 Jan-Dec;39:15333175241255744. doi: 10.1177/15333175241255744. Am J Alzheimers Dis Other Demen. 2024. PMID: 38764310 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous